Karyopharm Therapeutics (KPTI) Inventory Average (2019 - 2025)

Karyopharm Therapeutics has reported Inventory Average for 7 years, with the latest figure at $4.0 million in Q4 2025.

• For the quarter ending Q4 2025, Inventory Average fell 14.95% year-over-year to $4.0 million; the trailing twelve-month figure through Dec 2025 stood at $4.0 million (down 14.95% YoY), and the FY2025 full-year result was $4.4 million, up 12.79% from the prior year.
• Inventory Average for Q4 2025 stood at $4.0 million, down from $4.5 million in the prior quarter.
• The five-year high for Inventory Average was $4.9 million in Q2 2025, with the low at $2.9 million in Q1 2021.
• Historically, Inventory Average has averaged $3.9 million across 5 years, with a median of $4.0 million in 2021.
• Annual changes were most pronounced in 2021 — Inventory Average jumped 337.54% — and 2024, when it fell 27.81%.
• Karyopharm Therapeutics' Inventory Average stood at $4.0 million in 2021, then climbed by 5.27% to $4.2 million in 2022, then declined by 27.44% to $3.1 million in 2023, then surged by 53.07% to $4.7 million in 2024, then decreased by 14.95% to $4.0 million in 2025.
• The last three Inventory Average figures came in at $4.0 million (Q4 2025), $4.5 million (Q3 2025), and $4.9 million (Q2 2025), per Business Quant data.